CStone Pharmaceuticals is an investment holding company primarily engaged in the research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.